Bristol-Myers Squibb Co.

NYSE:BMY   3:59:58 PM EDT
-0.44 (-0.68%)
4:09:00 PM EDT: $64.38 +0.12 (+0.19%)

U.S. FDA Approves Bristol-Myers Squibb Co And bluebird bio Inc's Abecma

Published: 03/27/2021 04:26 GMT
Bristol-Myers Squibb Co. (BMY) - U.S. Food and Drug Administration Approves Bristol Myers Squibb’s and Bluebird Bio’s Abecma (idecabtagene Vicleucel), the First Anti-bcma Car T Cell Therapy for Relapsed Or Refractory Multiple Myeloma.